Related Experiment Video
Updated: Mar 15, 2026
09:03
Manufacture and Drug Delivery Applications of Silk Nanoparticles
Published on: October 8, 2016
16.7K
Dextran-based therapeutic nanoparticles for hepatic drug delivery
Friedrich Foerster1,2, Denise Bamberger3, Jonathan Schupp4
1Institute of Translational Immunology & Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg-University Mainz, Langenbeckstraße 1, 55131 Mainz, Germany.
Nanomedicine (London, England)
|September 16, 2016
Summary
Dextran-based nanoparticles (DNP) effectively target liver myeloid cells, including macrophages and dendritic cells, without toxicity. These versatile nanoparticles show promise as a drug delivery system for liver-specific therapies.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Immunology
Background:
- Targeted drug delivery systems are crucial for effective treatment of liver diseases.
- Myeloid cells, including macrophages and dendritic cells, play key roles in liver immunity and disease pathogenesis.
- Dextran-based nanoparticles (DNP) offer potential as biocompatible carriers for therapeutic agents.
Purpose of the Study:
- To evaluate dextran-based nanoparticles (DNP) as a drug delivery system for targeting liver myeloid cells.
- To assess the in vitro and in vivo characteristics of DNP, including toxicity, cellular uptake, and biodistribution.
Main Methods:
- Synthesis and optional PEGylation of dextran-based nanoparticles (DNP).
- In vitro assessment of DNP toxicity and cellular uptake by myeloid cells.
- In vivo evaluation of biodistribution and cellular uptake of empty and siRNA-carrying DNP in a liver model.
Main Results:
- DNP were readily internalized by myeloid lineage cells in vitro without affecting cell viability.
- In vivo studies demonstrated significant liver distribution of DNP, targeting approximately 70% of liver macrophages and dendritic cells after a single administration.
- Serum parameters confirmed the absence of in vivo toxicity associated with DNP treatment.
Conclusions:
- Dextran-based nanoparticles (DNP) are multifunctional and liver-specific drug carriers.
- DNP exhibit a favorable safety profile, lacking significant toxic side effects.
- DNP hold potential for clinical applications aimed at targeting liver macrophages and other myeloid cells.
Keywords:
PEGylationbiodegradabledendritic celldextrandrug deliveryliver targetingmacrophagenanoparticlessiRNAMore Related Videos
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
79
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
79
01:24Modified-Release Drug Delivery Systems: Site-Targeted
70
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
70
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
310
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
310
01:21Drug Distribution: Tissue Binding
4.3K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
4.3K
01:18Transdermal Drug Delivery Systems
94
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
94
01:14Hepatic Drug Clearance: Role of Transporters
359
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
359